Rigrodsky & Long, P.A. Investigates Martek Biosciences Corporation Buyout

  • Do you own Martek Biosciences Corporation common stock?
  • Did you purchase your shares prior to December 21, 2010?
  • Do you feel the buyout is unfair?
  • Do you want to discuss your rights?

If the answer to these questions is "yes," please contact the deal lawyers at Rigrodsky & Long, P.A. ("R & L") today to schedule a FREE consultation. Just call us, or fill out our contact form so that we can call at your convenience. Your consultation will not create any obligation to use our services at any time.

Contact R & L today to be sure your best interests are being protected.

R & L is national law firm with decades of combined legal experience. R & L is investigating potential claims against the board of directors of Martek Biosciences Corporation concerning possible breaches of fiduciary duty and other violations of law related to the Company’s entry into an agreement to be acquired by Royal DSM N.V. in a transaction valued at approximately $1.087 billion.

Click here to read the full press release.

Rigrodsky & Long, P.A. Investigates Martek Biosciences Corporation Buyout

Rigrodsky & Long, P.A. announces that it is investigating potential claims against the board of directors of Martek Biosciences Corporation (“Martek” or the “Company”) (Nasdaq: MATK) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s entry into an agreement to be acquired by Royal DSM N.V. (NYSE Euronext: DSM KON) (“DSM”) in a transaction valued at approximately $1.087 billion.

Under the proposed agreement, DSM will commence a cash tender offer to acquire Martek’s outstanding shares of common stock at $31.50 per share in cash. The tender offer is expected to commence between January 10, 2011 and January 25, 2011.

The investigation concerns whether Martek’s board of directors failed to adequately shop the Company and obtain the best price possible for Martek’s shareholders before entering into the agreement with DSM. When Martek reported its fourth quarter and fiscal year 2010 financial results on December 8, 2010, Company Chief Executive Officer Steve Dubin commented: “Martek’s fourth quarter came in at the high end of our expectations and concluded a year of many accomplishments for Martek. Revenue grew across all business segments in 2010, our core infant formula ingredients business was strengthened through the extension of the terms of two of our key infant formula sole source supply agreements, and significant improvements on the operational side of the business were implemented which helped drive growth in both margins and income.”

If you own the common stock of Martek and purchased your shares before December 21, 2010, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky, Esquire or Noah R. Wortman, Case Development Director, of Rigrodsky & Long, P.A., 919 N. Market Street, Suite 980, Wilmington, Delaware, by telephone at (888) 969-4242, or by e-mail to info@rigrodskylong.com.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

R & L, with offices in Delaware and New York, litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Learn more about R&L:  Visit Our WebsiteOur Firm  |  Our Practice Areas  |  FAQ's

Fill out the form below or call us toll-free at 888-969-4242, for a FREE no-obligation consultation.